Randomized optimal selection design for dose optimization
From MaRDI portal
Cites work
- A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies
- BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints
- Design and sample size determination for multiple-dose randomized phase II trials for dose optimization
- DROID: dose-ranging approach to optimizing dose in oncology drug development
This page was built for publication: Randomized optimal selection design for dose optimization
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6905124)